If you have a type of bone marrow disease called myelofibrosis, a healthcare provider may prescribe ruxolitinib (Jakafi™). But what is this medicine and how does it work?
Ruxolitinib is the first medication approved to treat myelofibrosis, a disease that causes scarring in the bone marrow, which interferes with the ability of the bone marrow to make blood cells. This drug can help relieve symptoms of myelofibrosis and help reduce an enlarged spleen. Ruxolitinib is made by DSM Pharmaceuticals, Inc., for Incyte Corporation.
Available in tablet form, ruxolitinib is typically taken twice daily. Side effects may include bruising, headaches, and dizziness.
(Click Ruxolitinib for more details on what this drug is used for and how it works. This article also covers dosing instructions, general safety precautions to be aware of, and possible side effects to look out for.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Jakafi [package insert]. Wilmington, DE: Incyte Corporation;2011 November.
Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. A, J Hematol 2011. 86: 1017-1026.
Tefferi A. Prognosis and treatment of primary myelofibrosis. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011.
Food and Drug Administration (FDA) news release. FDA approves first drug to treat a rare bone marrow disease. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280102.htm. Accessed December 5, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click